Certolizumab pegol for the treatment of Crohn’s disease

By Stefan Schreiber. Therapeutic Advances in Gastroenterology, 2011

600 citations recorded by the source corpus.

Subfields: Epidemiology, Genetics, Hematology

View Paper: https://www.semanticscholar.org/paper/27fd0bded0d273818ca5dcad2b2763a8edacaa18

Citations in the corpus

• scFv Antibody: Principles and Clinical Application (2012, unknown): “Efficacy of Certolizumab Pegol was supported by phase III clinical trial which was compared with the placebo [133].”